KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Gross Margin (2016 - 2025)

Jazz Pharmaceuticals has reported Gross Margin over the past 16 years, most recently at 87.18% for Q4 2025.

  • Quarterly Gross Margin fell 99.0% to 87.18% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 116.64% through Dec 2025, up 2760.0% year-over-year, with the annual reading at 88.21% for FY2025, 84.0% down from the prior year.
  • Gross Margin was 87.18% for Q4 2025 at Jazz Pharmaceuticals, down from 88.56% in the prior quarter.
  • Over five years, Gross Margin peaked at 93.39% in Q1 2021 and troughed at 82.67% in Q3 2021.
  • The 5-year median for Gross Margin is 88.17% (2024), against an average of 87.44%.
  • Biggest five-year swings in Gross Margin: crashed -1012bps in 2021 and later soared 662bps in 2023.
  • Tracing JAZZ's Gross Margin over 5 years: stood at 84.82% in 2021, then decreased by -2bps to 82.78% in 2022, then grew by 8bps to 89.4% in 2023, then fell by -1bps to 88.17% in 2024, then dropped by -1bps to 87.18% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 87.18%, 88.56%, and 88.88% for Q4 2025, Q3 2025, and Q2 2025 respectively.